Objective: To evaluate the efficacy and safety of an a-lactalbumin-enriched formula with a protein profile and total protein concentration closer to human milk (HM) and lower than conventional formulas. Subjects/methods: Two hundred and sixteen healthy, term infants, p14 days post-natal age were enrolled and 166 (76.9%) completed the study. Timed post-prandial plasma essential amino-acid levels were determined after 8 weeks of ad libitum study feeding. Study events were assessed every 2 weeks. Results: At 8 weeks, all mean plasma essential amino-acid levels in the experimental formula (EF) group were as high as the standard formula (SF) and HM groups. The incidence of feeding-related gastrointestinal (GI) events varied significantly (P ¼ 0.025) across groups: SF (31.3%), EF (17.2%) and HM (13.6%), with SF being significantly higher than HM (P ¼ 0.015). Study withdrawals due to feeding-related GI events were significantly different (P ¼ 0.001) across groups: SF (12.5%), EF (4.7%), and HM (0%). The timing of GI events was also significantly different across groups (P ¼ 0.010). Conclusion: The study demonstrated that feeding a higher quality, lower protein concentration formula (a-lactalbuminenriched) met all essential amino acid and protein requirements of infants. The GI tolerance profile of infants receiving the EF was similar to HM-fed infants.
Introduction
Human milk (HM) is the preferred sole source of nutrition for at least the first 6 months of life (World Health Organization, 2003) . If a mother cannot or chooses not to breast-feed during this period, an infant formula should be fed as the alternative. The composition and physiological effects of infant formula differ from HM and, therefore, the goal of infant formula development is to mimic both the composition and function of HM. HM and infant formula differ substantially in protein composition and concentration. Mature (41 month lactation) HM provides 9-11 g/l protein (Dewey et al., 1996) , while conventional infant formulas contain 15 g/l. A key objective of infant formula development is to reduce the total protein concentration while meeting the essential amino acid needs of the infant.
a-Lactalbumin is the predominant whey protein found in HM with a concentration of 2-3 g/l (Jackson et al., 2004) while it is a relatively minor component of bovine milk whey. b-Lactoglobulin, a protein not normally found in HM, is the primary bovine whey protein (Rudolff and Kunz, 1997) . a-Lactalbumin has both a biochemical role and a nutritional role for the mother-infant dyad. During lactation, the mammary gland produces a-lactalbumin and galactosyltransferase. These two proteins form the enzyme complex lactose synthase, which catalyzes the synthesis of lactose from glucose and galactose (Brodbeck et al., 1967) . After the completion of lactose synthesis, a-lactalbumin dissociates from the enzyme complex and becomes an integral part of the protein content of HM (approximately 41% of the whey protein and 28% of the total protein; Heine et al., 1991) . The nutritional value of a-lactalbumin lies in its high proportion of essential amino acids, specifically tryptophan, cysteine and lysine (Lonnerdal, 1994) . Generally, tryptophan is the limiting essential amino acid in infant formula (Heine et al., 1996) . In addition to being an essential amino acid required for protein synthesis, tryptophan is also the precursor to the neurotransmitter serotonin (Lien, 2003) .
Recent advances in dairy milk separation technology have resulted in the development of a process that yields whey protein fractions with a substantially higher concentration of a-lactalbumin (69%) than standard bovine whey and a 59% reduction of b-lactoglobulin. a-Lactalbumin-enriched formulas produced with this whey fraction can have lower protein levels than conventional formulas due to its higher protein quality (amino-acid profiles more similar to HM). Lien et al. (2004) conducted a 12-week growth and safety study comparing a formula enriched in a-lactalbumin [experimental formula (EF)] to a standard formula (SF). Growth and serum albumin levels were comparable between the formulas even though the EF had lower total protein than the SF. The current study was undertaken as follow-up research to the aforementioned study , to evaluate the protein quality and quantity of the a-lactalbumin-enriched formula (experimental formula, EF), by measuring post-prandial plasma essential amino-acid levels in healthy term infants receiving EF, SF or HM during an 8-week period. In addition, the present study conducted a rigorous assessment of GI tolerance.
Materials and methods
A prospective, multicenter, masked, randomized clinical trial was undertaken to compare the plasma essential amino-acid levels of infants fed one of three regimens: a standard wheydominant infant formula (SF); an EF containing lower total protein and increased a-lactalbumin concentrations (EF) and HM-fed. The Institutional Review Boards (IRBs) of the participating centers approved the study protocol. Written informed consent was obtained from the parent or legal guardian of each infant before enrollment into the study.
Study population
Infants p14 days post-natal age were included if they were healthy, born at term and appropriate for gestational age; had weight for length at birth within the 10th and 90th percentiles according to growth charts provided by the US Center for Disease Control (CDC); had weight for length at enrollment within the 10th and 90th percentiles according to CDC growth charts; and were exclusively fed infant formula or exclusively breast fed. Infants in the formula groups were excluded if they were partially or exclusively fed HM within 2 days of enrollment were routinely fed either baby food or solid foods, had siblings with feeding problems that had necessitated a change from a bovine milk-based formula to a protein hydrolysate or soy formula, had conditions that required feedings other than those specified in the protocol, had any major congenital malformation, had suspected or documented systemic or congenital infections [such as Human immunodeficiency virus (HIV)]; had cardiac, respiratory, hematological, gastrointestinal (GI) or other systemic diseases; or had participated in another clinical trial. All routine immunizations, vitamin supplements and overthe-counter medications were permitted. Mineral, protein and herbal supplements (except fluoride) were prohibited.
Study feedings
Total protein concentration was 15 g/l (2.2 g protein/ 100 kcal) in the SF and 14 g/l (2.08 g protein/100 kcal) in the EF. The essential amino-acid composition of EF was closer to that of HM than SF for six amino acids (Table 1) . No free amino acids were added to either formula. Final formula concentration of a-lactalbumin was 2.2 g/l in EF and 1.3 g/l in SF, while the b-lactoglobulin concentration of EF was substantially reduced in comparison to SF and other current whey-dominant infant formulas. Mean non-protein nitrogen (NPN) content of EF was 12.61% (87.39% protein nitrogen) compared to the mean NPN content of SF of 16.55% (83.45% protein nitrogen). The carbohydrate (lactose), fat and caloric content of the EF and SF were the same (73.0 g/l, 36.0 g/l and 672 kcal/l, respectively). EF and SF had identical levels of vitamins, nucleotides, taurine and the long-chain omega-3 and omega-6 polyunsaturated fatty acids, docosahexaenoic and arachidonic acids (DHA and AA). The composition of the fat blend was the same for both the EF and SF (a blend of palm olein, oleic, coconut and soy oils with 0.21 w% and 0.34 w% of total fatty acids as DHA and AA, respectively). The nucleotide concentration was the same for both EF and SF (cytidine-, uridine-, adenosine-, guanosine-and inosinemonophospate concentrations were 16.5, 5.0, 4.0, 2.0 and 2.0 mg/l, respectively). Calcium concentration of EF was 
Randomization
A computerized randomization/enrollment system was used to assign study formula. Infants were randomly assigned to receive either EF or SF ad libitum for 8 weeks. The HM group was assigned study numbers, but not randomized. If an infant was withdrawn from the study, the randomization number and corresponding formula assignment were not reassigned to another infant.
Efficacy and safety parameters
Primary efficacy parameters were post-prandial plasma essential amino-acid levels (arginine, cysteine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan (free), tyrosine and valine) at week 8. For plasma amino-acid evaluation, a 1.5 ml blood sample was collected by venipuncture in a heparinized tube, between 1.5 and 2.5 h after the infant's most recent study feeding (HM or study formula). Amino-acid analysis was conducted by automated ion-exchange chromatography and compared to reported normative values (Lepage et al., 1997) . Secondary efficacy parameters included markers of protein status (albumin, blood urea nitrogen (BUN), creatinine and complete blood count with differential). For protein status evaluation, a 1.5 ml blood sample was collected either by venipuncture or heel stick in an ethylenediaminetetraacetic acid treated vacutainer or microtainer tube. Blood samples were centrifuged at 3000 r.p.m. Â 15 min, plasma was transferred to labeled vials and shipped frozen (À201C) to Mayo Central Laboratory for Clinical Trials (Rochester, MN, USA). Primary safety parameters were the study events associated with each study feeding and growth. This study was conducted in accordance with the International Conference on Harmonization (ICH) and Good Clinical Practice (GCP) guidelines for the registration of pharmaceutical products for human use. Consistent with ICH/GCP guidelines, any unintended change in pathology or in anatomic, metabolic or physiologic functioning temporally associated with consumption of formula or HM during the study was defined as a study event. These changes were reflected by physical signs, reported symptoms or laboratory data. Any event consistent with the above definition reported by the caregiver or noted by study site personnel were collected as a study event. Study events were categorized as 'Any Causality', meaning all events regardless of causality, or 'feeding-related'. Feeding-related events were defined as those, in the opinion of the study physician, were definitely, probably or possibly related to study feeding. Primary safety parameters were recorded during scheduled visits at weeks 4 and 8, and by telephone contacts at weeks 2, 6 and 10. Growth parameters, infant weight (g), length (cm), weightfor-length ratio and head circumference (cm) were measured at baseline (enrollment) and weeks 4 and 8. Infants were weighed without diapers to the nearest 0.01 kg. Growth velocity parameters, change in weight (g/day), length (cm/week) and head circumference (cm/week), were calculated using anthropometric data from baseline (enrollment) and week 8. Secondary safety parameters included evaluation of the acceptability and tolerance of study formulas by caregivers at each study time point.
Statistical analysis
Data were analyzed according to the intent-to-treat (ITT) principle. The ITT set included data from all infants who entered the study and received at least one feeding of study formula. All data were analyzed using SAS statistical software (SAS, Cary, NC, USA). Categorical variables were summarized with frequencies and percentages. Continuous variables were summarized with sample number (n), mean, s.d. and 95% confidence interval around the mean. Three-way analysis of variance (ANOVA) and three-way analysis of covariance (ANCOVA) were used to assess anthropometric data (weight, length and head circumference) at birth, baseline and weeks 4 and 8; gestational age and gender at baseline; protein status (albumin) and laboratory safety data at baseline and week 8. A Student's t-test was used to test for differences in plasma amino-acid levels between EF and SF. Given the multiple t-tests performed, significant results were calculated and presented at the traditional level (a ¼ 0.05) and using the Bonferroni adjustment for multiplicity (a ADJ ¼ 0.004). A three-way ANOVA was used to test for differences in GI study event incidence and study withdrawals across groups. Where differences were found, a Fisher's exact test was used to test for differences between two groups. A Kalpan-Meier survival curve was used to estimate the total GI study events and their occurrences over the study period for each study group (including continued estimated GI study events for study withdrawal infants) as a method to look at cumulative incidence. Log-rank test was used to rank order the cumulative incidence of GI study events per group over the study period and to compare the differences in the three study groups over time.
Weight-for-age measurements at baseline and weeks 4 and 8 were used to assess body weight of study infants relative to CDC reference curves (Dibley et al., 1987; Kuczmarski et al., 2000) . Length-for-age, and weight-for-length z-scores were evaluated at baseline and week 8. Epi-Info 2000 software (Version 1.1, CDC and Prevention, 2000) was used to determine z-score values. Any infant with a missing value for a particular variable was not included in the analyses involving that variable.
Results
Infant demographic and disposition data are summarized in Table 2 . Of the 216 infants enrolled in the study, 64 (29.5%) received SF, 64 (29.5%) received EF and 88 received HM (41%). Forty-three (67.2%) infants were fed SF, 49 (76.6%) were fed EF and 74 (84.1%) were fed HM and completed the study. The most common reason for study discontinuation was due to study events: 21.9% of the SF group discontinued due to a study event, compared to 10.9% of the EF group; no infants in the HM group discontinued due to a study event.
Thirty-four (53.1%) infants in the SF group and 35 (54.7%) in the EF group were females (NS). The mean age at enrollment, and birth growth parameters (birth weight, birth length and birth head circumference) were similar among all three groups. The mean gestational age of the HM group was higher than the two formula groups (P ¼ 0.036). There were no statistically significant differences among the three treatment groups in growth velocity from baseline to week 4 or week 8 (Table 3) . Mean changes from baseline to week 8 z-scores were similar across study groups. There were no significant differences between the two formula groups in mean formula intake (SF versus EF at 8 weeks: 10327258 versus 9907228 ml/day, respectively).
There were no statistically significant differences across treatment groups in the serum concentrations of albumin or creatinine at baseline or week 8. The mean albumin concentration was similar among groups at baseline (SF: 3.870.3 g/dl, EF: 3.870.3 g/dl and HM: 3.770.4 g/dl) and week 8 (SF: 4.170.3 g/dl, EF: 4.170.2 g/dl and HM: 4.070.2 g/dl). The mean creatinine concentration was similar among groups at baseline (SF: 0.570.2 mg/dl, EF: 0.570.1 mg/dl and HM: 0.570.3 mg/dl) and week 8 (SF: 0.570.1 mg/dl, EF: 0.470.1 mg/dl and HM: 0.570.2 mg/dl). Serum BUN measured at baseline and 8 weeks were within normal ranges for all study groups. There was a statistically significant (Po0.001) difference in the BUN concentration among study groups at week 0 (SF: 7.773.3 mg/dl, EF: 7.273.0 mg/dl and HM: 10.773.8 mg/dl) and week 8 (SF: 9.471.9 mg/dl, EF: 9.571.9 mg/dl and HM: 6.872.6 mg/dl). There were no significant differences in hematocrit or hemoglobin concentrations among groups at weeks 0 or 8 (data not shown). Table 4 represents the mean post-prandial concentrations of plasma essential amino acids at week 8 among infants receiving SF, EF and HM for the ITT analysis. There were no significant differences in plasma amino-acid concentrations between infants fed EF versus SF for 8 of 12 amino acids. For the remaining four amino acids (cystine, lysine, tryptophan and tyrosine), the means were higher in the EF group; however, they were within the normal range for healthy infants of similar age (Lepage et al., 1997) . One hundred and seventy-seven of the 216 infants enrolled (81.9%) experienced a study event (see Materials and methods section). There was no statistically significant difference in the number of infants reporting a study event (overall) among the treatment groups. The most common body system reported for study events was the GI system. The most common GI study events were eructation, constipation, gastroesophageal reflux, abdominal pain, vomiting, diarrhea and regurgitation. Figure 1 depicts the incidence of infants that experienced a GI study event of any causality and the incidence of infants that experienced a feeding-related GI study event. The incidence of GI study events of any causality was highest for the SF group (56.3%) and lower for the EF and HM groups (39.1 and 40.9%, respectively); however, this difference did not reach statistical significance (P ¼ 0.092). The incidence of constipation (SF 18.8%, EF 9.4% and HM 6.8%) and regurgitation (SF 9.4%, EF 3.1% and HM 3.4%), for study events of any causality, were substantially lower in the EF group than the SF group (data not shown). A similar trend was observed in the incidence of constipation for feeding-related study events (data not shown). Feeding-related GI study events ( Figure 1 ) were significantly different (P ¼ 0.025) across treatment groups. The incidence of feeding-related GI study events was highest for the SF group (31.3%), followed by the EF and HM groups at 17.2 and 13.6%, respectively. A Fisher's exact test showed the incidence of feeding-related GI study events was significantly higher in the SF versus HM group (P ¼ 0.015). Figure 2 depicts the incidence of study withdrawals due to GI study events. A significant difference across treatment groups was found for study withdrawals due to GI study events of any causality (Po0.001) and feedingrelated GI study events (P ¼ 0.001) (Figure 2 ). For both variables, the incidence of study withdrawals was highest for the SF group and lowest for the HM group. Figure 3 shows the cumulative incidence (%) of GI study events over time. There was a significant difference (P ¼ 0.010) in the timing of GI study events incidence among all groups, based on the log-rank test. For the SF group, GI study event incidence occurs relatively frequently near the beginning of the study (between days 1 and 20) and remains higher for the duration of the trial. For the EF group, the Figure 1 Incidence of GI study events among all feeding groups. a The incidence of GI study events of any causality was not significantly different across feeding groups (ANOVA, P ¼ 0.092). b The incidence of feeding-related GI study events was significantly different across feeding groups (ANOVA, P ¼ 0.025). Figure 2 Incidence of study withdrawals due to GI study events among all feeding groups. a The incidence of study withdrawals due to GI study events of any causality was significantly different across groups (ANOVA, Po0.001). The incidence of study withdrawals due to feeding-related GI study events was significantly different across groups (ANOVA, P ¼ 0.001). The incidence of study withdrawals due to feeding-related study events was significantly higher in the SF versus HM group (Fisher's exact test, P ¼ 0.001). ANOVA, analysis of variance; GI, gastrointestinal; HM, human milk; SF, standard formula. p=0.010 Log-rank test 60 Figure 3 Time to incidence of GI study events by feeding group.
There was a significant difference (P ¼ 0.010) in the timing of GI events among the feeding groups (log-rank test). For the SF group, GI events occurred relatively frequently near the beginning of the study (days 1-20) and less frequently near the end of the study (days 40-60). For the HM group, GI events occurred relatively frequently near the beginning of the study (days 1-15) and in a more linear manner (days 50-60). For the EF group, the incidence pattern of GI events was similar to that of the HM group after day 18. EF, experimental formula; GI, gastrointestinal; HM, human milk; SF, standard formula.
a-Lactalbumin-rich infant formula AM Davis et al incidence pattern of GI study events was similar to that of the HM fed infant after an initial period of adjustment (18 days).
Discussion
A key goal as well as a major challenge of infant formula research is to design formulas that mimic HM both in its composition and physiologic effects. Traditionally, infant formulas contain a higher protein concentration than HM to provide formula-fed infants with sufficient quantities of each essential amino acid. Data from the present study demonstrated that all essential amino acid requirements were met with an a-lactalbumin-enriched formula containing a lower total protein content than conventional formulas. The plasma amino-acid levels of infants receiving the EF were within the range of infants receiving SF and HM. Additionally, EF-fed infants had a GI tolerance profile similar to HMfed infants as demonstrated by the incidence and timing of GI events. Creating an infant formula with a protein profile closer to HM is an ongoing challenge of infant formula research. Various studies have evaluated infant formula protein systems in an attempt to more closely imitate HM, both in protein content and in the infant's post-prandial plasma amino acid patterns. Janas et al. (1987) evaluated formulas with lower protein/energy ratios (1.8 g protein/ 100 kcal, versus SF levels of 2.2 g protein/100 kcal) and with varying whey/casein ratios. Although some plasma aminoacid levels were similar to breast-fed controls, the levels of tryptophan in all groups receiving formula were significantly lower than the breast-fed group. Picone et al. (1989) evaluated two lower protein formulas (11 and 13 g/l) compared to a standard protein formula group (15 g/l) and a breast-fed group. They found that both of the reducedprotein formula groups had lower plasma tryptophan levels as compared to the SF and breast-fed groups. In contrast to the above results, other studies have found similar plasma tryptophan levels compared to breast-fed infants after feeding term infants lower protein formulas (Lonnerdal and Chen, 1990; Karlsland Akeson et al., 1998; Lonnerdal and Hernell, 1998) . The inconsistent results may be due to differences between formulas with regards to formula processing techniques or heat treatment that affect protein digestibility (Lonnerdal and Hernell, 1998) . A number of further studies have evaluated lower protein formulas with the addition of free tryptophan. Two studies (Fazzolari-Nesci et al., 1992 and Hanning et al., 1992) compared a control whey-dominant protein formula (15 g/l), both to an EF with added tryptophan (13 g/l protein, whey to casein ratio of 40:60), and to HM. While the mean plasma tryptophan levels in the group receiving the control formula were significantly lower than breast-fed infants, the levels in the supplemented groups were similar to the breast-fed infants. However, addition of free amino acids to infant formula should take into consideration that a sodium-dependent transport system is required for free amino-acids absorption whereas dipeptides and tripeptides (the primary products of intestinal protein digestion) are absorbed without a dependent transport system (Wenzel et al., 2001) . Ingestion of small peptides has been found to appear in plasma more rapidly and uniformly as compared to free amino acids using the same amino-acid pattern (Svangerb et al., 1977) . HM only contains about 5% free amino acids (Rerat, 1995) mainly as glutamic acid and taurine (Pamblanco et al., 1989; Agostini et al., 2000) , and therefore departure from the HM model by adding free amino acids to formula requires careful consideration.
In the present study, sufficient tryptophan was provided in a lower protein formula (EF) via enrichment with the protein a-lactalbumin. The mean post-prandial serum concentration of tryptophan in the EF group was higher than that of the SF and HM groups, but was within 1 s.d. of the means of both groups. Heine et al. (1996) found serum tryptophan concentrations similar to the levels observed in the EF group, using a formula with a similar amount of a-lactalbumin in their formula (2.2 g/l, 13.4 g protein/l).
In addition to lowering the protein concentration of EF closer to HM, the enrichment of infant formula with the whey protein a-lactalbumin results in whey protein composition closer to that of HM. HM whey proteins play an important role in many physiologic activities that benefit the infant such as immune function and nutrient absorption (Lonnerdal and Lien, 2003) . a-Lactalbumin in HM has been shown to bind minerals such as calcium (Lonnerdal and Glazier, 1985) and zinc (Ren et al., 1993) facilitating their absorption (Lonnerdal and Lien, 2003) . Increased absorption of zinc and iron has been shown in rhesus monkeys fed an infant formula enriched with a-lactalbumin (Kelleher et al., 2003) . The ability of a-lactalbumin to enhance mineral absorption from our formula matrix warrants further investigation.
Improving the GI tolerance profile of formula-fed infants' closer to that of HM-fed infants is another goal of infant formula development. Formula tolerability is frequently assessed by the comparison of the numbers and kinds of GI study events (Alarcon et al., 2002) ; these are present in all infants and may differ between breast-fed and formula-fed infants (Lloyd et al., 1999) . The unique finding in the present study was that the cumulative GI event profile of EF was similar to that of the HM profile after study day 18. Additionally, the timing of GI study events suggests that the SF was not as well tolerated when compared to HM. GI effects usually present soon after the introduction of a new feeding (Lloyd et al., 1999) , and to our knowledge, a detailed time course of study events has never before been reported. Of potential clinical importance is that the incidence of constipation and regurgitation in the EF group was similar to HM-fed infants, and lower than that of the SF group. The improved GI profile observed in the present study may be attributed to a formula matrix that is closer to HM. This outcome complements the findings of the a-lactalbumin growth and safety study where Lien et al. (2004) found improved tolerance in infants fed with a-lactalbuminenriched formula, as demonstrated by superior acceptability and tolerance (% satisfactory) ratings in EF versus SF after week 2, and a significantly higher rating at week 8 (EF: 97% and SF: 89%).
In conclusion, this study of a lower protein infant formula with increased a-lactalbumin concentration represents a major improvement in the infant formula protein matrix to more closely match the protein composition and GI tolerance profile of HM. The formula enriched with a-lactalbumin delivered lower total protein with higher protein quality as demonstrated by the comparable plasma essential amino-acids profiles compared to a group who received a conventional formula. Moreover, given that the mean post-prandial plasma concentrations of nearly all amino acids in EF-fed infants were higher than HM-fed infants, a further reduction of the protein concentration of this formula may be feasible. Lastly, the a-lactalbuminenriched (EF) formula demonstrated improved GI tolerance over SF with significantly fewer GI study events and a similarity in the cumulative incidence and timing of GI study events to that of HM-fed infants.
